|
|
Volumn 344, Issue , 2012, Pages
|
|
US judge fines Johnson & Johnson $1.1bn for misleading marketing of risperidone.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEUROLEPTIC AGENT;
RISPERIDONE;
ADVERTIZING;
DRUG INDUSTRY;
ECONOMICS;
HUMAN;
JURISPRUDENCE;
LEGAL ASPECT;
MARKETING;
METHODOLOGY;
NOTE;
POSTMARKETING SURVEILLANCE;
UNITED STATES;
ADVERTISING AS TOPIC;
ANTIPSYCHOTIC AGENTS;
DRUG INDUSTRY;
HUMANS;
JURISPRUDENCE;
MARKETING;
PRODUCT SURVEILLANCE, POSTMARKETING;
RISPERIDONE;
UNITED STATES;
|
|
EID: 84861925989
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.e2772 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
